Gore, CVRx get CE marks; A smartphone sensor to detect vitamin deficiencies;

@FiercePharma: Germany bans dozens of drugs made by Dr. Reddy's, Unichem, others because of issues at GVK Bio. Story | Follow @FiercePharma

@CarlyHFierce: New financing helps Anergis take allergy vaccine to Phase III. More | Follow @CarlyHFierce

> Gore got a CE mark for its Viabahn endoprosthesis to improve blood flow in symptomatic obstruction of peripheral veins, excluding the venae cavae and pulmonary veins. Release

> Baxter ($BAX) filed an SEC form confirming a mid-2015 spinoff of its biopharmaceutical business. Release

> CVRx received CE mark to expand labeling of the Barostim neo System as safe for use MRI scans, benefiting patients receiving Barostim Therapy for heart failure or resistant hypertension. Release

> Vitastiq developed a sensor that works in conjunction with a smartphone app to measure a person's vitamin content by passing a sensor over their skin. Story

> The NIH Pain Consortium dsicussed research standards for chronic low-back pain to address the challenge of comparing data across different studies. Release

Medical Device News

@FierceMedDev: Startup gains FDA clearance for breast surgery guidance system. Story | Follow @FierceMedDev

@EmilyWFierce: C.R. Bard battling bid from plaintiffs to consolidate pelvic mesh suits. More | Follow @EmilyWFierce

> St. Jude gains CE mark for first pacemaker with MultiPoint Pacing. Article

> Omron partnership to give AliveCor more retail punch. News

Biotech News

@FierceBiotech: Amicus eyes a 2015 EU filing for its rare disease drug with FDA in sight. Article | Follow @FierceBiotech

@DamianFierce: The @nytimes digs into the medicinal ketamine issue, with cameos from Naurex, Cerecor and $JNJ. More | Follow @DamianFierce

> Naurex posts the positive PhIIb data that helped it reel in $80M. Story

> Merck hits a hiccup with its new Ebola vaccine. News

> Bellicum battles for CAR-T spotlight with a $121M IPO pitch. Article

Vaccines News

> Amgen tests T-Vec's combo potential in trial with Merck's Keytruda. More

> Merck Vaccines president Gerberding leaving post for EVP role. Item

> Ebola vaccine makers Merck, GSK, J&J get legal protections in U.S. thanks to HHS declaration. Report

> Merck wins FDA approval for Gardasil follow-up. Story

> PaxVax meets primary endpoints in PhIII cholera vaccine trial. Article

Pharma Manufacturing News

> AstraZeneca closing U.S. plant, costing 180 jobs. Story

> More Novartis jobs cut in New York as plant suffers drawn-out drawdown. Report

> Romark building $110M plant in Puerto Rico. More

> Indonesia's Indofarma and Kimia combine manufacturing, supply chain strengths. News

> Indian drugmakers lambast proposed PET packaging ban. Article

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.